CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Zentalis Q3 net loss widens 8% year over year to $28.82 million

By Public Technologies
  • Zentalis Pharmaceuticals’ third-quarter 2026 net loss widened 8% year-over-year to $28.82 million.
  • Total operating expenses fell 8% year-over-year to $31.15 million.
  • Cash, cash equivalents and marketable securities totaled $228.89 million at September 30, providing expected runway into the first half of 2028.
  • DENALI Part 2c enrollment should finish in November 2026, with integrated topline results expected in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091605PRIMZONEFULLFEED9873614) on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk